Total medical devices industry cross border deals worth $4.3bn were announced globally for November 2021, with the $2.49bn acquisition of Atos Medical being the sector’s biggest investment, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 40.9% over the previous month of $3.03bn and a drop of 37.2% when compared with the last 12-month average of $6.8bn.
In terms of number of cross border deals, the sector saw a rise of 3.77% with 55 deals in November 2021 when compared to the last 12-month average of 53 deals.
In value terms, Europe led the activity with cross border deals worth $2.67bn in November 2021.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDatamedical devices industry cross border deals in November 2021: Top deals
The top five cross border deals accounted for 81.3% of the overall value during November 2021.
The combined value of the top five cross border deals stood at $3.47bn, against the overall value of $4.3bn recorded for the month.
The top five medical devices industry cross border deals of November 2021 tracked by GlobalData were:
1) Coloplast $2.49bn acquisition deal with Atos Medical
2) The $475m acquisition of Ivantis by Alcon
3) Blue Bay capital,Boyu Capital Consultancy,Greater Bay Area Fund,Guoqi Investment,Jiangsu Jiequan ABC State-owned Enterprise Mixed Ownership Reform Fund,LYFE Capital,Mirae Asset Venture Investment,Morning One Investment,Octagon Capital Group,Orbimed Advisors,Sage Partners,Sanzheng Health Investment,Sequoia Capital China and Temasek Holdings (Private) $200m venture financing deal with Shenzhen Jingfeng Medical Technology
4) The $180m venture financing of Owkin by Sanofi
5) Atlas Venture,Casdin Capital,Cormorant Asset Management,Janus Henderson Investors,Newpath Management,Omega Fund Management,Sofinnova Partners,T Rowe Price Associates and Wellington ManagementLLP $125m venture financing deal with Chroma Medicine
